CMS Backs AI Spine Surgery: Carlsmed's Landmark Reimbursement Victory

CARLSBAD, CA – August 03, 2026 – In a move that reverberates from hospital boardrooms to Wall Street trading desks, Carlsmed, Inc. (Nasdaq: CARL) today confirmed a landmark policy victory. The Centers for Medicare & Medicaid Services (CMS) has finalized a favorable reimbursement structure for the company’s aprevo® Lumbar spinal fusion procedures, effectively creating a dedicated financial pathway for its AI-powered, personalized surgical technology. This decision is more than just a bureaucratic update; it's a powerful endorsement that promises to reshape the economics of advanced spinal care and accelerate the adoption of personalized medicine.

Effective October 1, 2026, the new policy carves out three new Medicare Severity-Diagnosis Related Group (MS-DRG) codes specifically for complex spinal fusions utilizing technology like aprevo®. For Carlsmed, a commercial-stage company that went public just over a year ago, this ruling is a critical de-risking event, providing the financial clarity hospitals need to adopt its innovative platform. For the broader medical technology landscape, it signals that CMS is willing to evolve its payment systems to keep pace with innovation.

The Greenlight: Deconstructing the CMS Decision

At the heart of the announcement is the creation of MS-DRGs 523, 524, and 525. Previously, hospitals performing an aprevo® procedure had to bill under existing, more generic spinal fusion codes. These codes often failed to capture the higher resource utilization—including advanced imaging, AI-driven surgical planning, and the manufacturing of a 3D-printed, patient-specific implant—inherent in Carlsmed's approach. This mismatch created a financial disincentive for hospitals, slowing the adoption of a technology designed to improve patient outcomes.

“This reimbursement decision represents a significant step forward in expanding hospital, surgeon and patient access to the aprevo® procedure,” said Mike Cordonnier, Chairman and CEO of Carlsmed, in the company’s official statement. “We appreciate CMS’ continued partnership to implement this policy.”

CMS’s rationale was to “improve the capture of beneficiary acuity and resource utilization,” a technical way of saying the old system didn’t pay enough for this level of complex work. By creating new, dedicated codes, CMS is acknowledging that personalized, data-driven surgery is fundamentally different and more resource-intensive than traditional methods using off-the-shelf implants. For hospital administrators, this translates into predictable and, crucially, adequate payment, transforming the aprevo® procedure from a financial risk into a viable service line.

From Niche to Norm: The Business Case for Personalized Spines

This policy change is the commercial catalyst Carlsmed has been working towards. With the reimbursement barrier significantly lowered, the company's path to market penetration is now clearer than ever. This is particularly vital for a company in its high-growth phase. In 2025, Carlsmed reported an impressive 85.9% year-over-year revenue increase to $50.5 million, a figure that demonstrates surging demand even before this favorable reimbursement landscape was secured. Now, with financial validation from the nation's largest healthcare payer, that growth trajectory is poised to accelerate.

Investors have taken note. Analysts have maintained a positive outlook on CARL, with price targets suggesting significant upside. This CMS decision will likely be seen as a fulfillment of a key strategic milestone, validating the company's long-term commercialization strategy. One healthcare financial analyst noted that such a ruling “removes the single largest adoption hurdle for new device technologies,” paving the way for a faster ramp-up in sales.

While this is a major win for Carlsmed, the company is not alone. The CMS ruling also applies to other advanced technologies, including the iFuse Bedrock™ Granite Implant System, indicating a broader validation of the entire category of complex, personalized spinal hardware. This suggests a rising tide that will lift multiple innovative boats, intensifying competition but also growing the overall market. Carlsmed's challenge now shifts from proving its value to the payer system to executing a flawless commercial rollout to capture market share.

The Technology Behind the Reimbursement

The CMS decision was not made in a vacuum. It is underpinned by the clinical promise of the aprevo® platform itself. Carlsmed’s technology, which has earned an FDA Breakthrough Device Designation, aims to solve the fundamental problem of spinal fusion surgery: the human spine is unique, but implants have historically been standardized. Using a patient's CT scan, Carlsmed's AI platform creates a detailed digital model of the spine and simulates various surgical corrections. This allows the surgeon to develop a precise, pre-operative plan. The plan is then used to 3D-print a sterile, patient-specific titanium implant designed for a perfect fit.

This precision-first approach is backed by compelling clinical data. In studies involving over 500 patients, the company reported that 82% of surgical levels achieved their target alignment within 5 degrees, a high degree of accuracy. Furthermore, 96% of cases showed zero implant subsidence—a common complication where the implant sinks into the bone—at the one-year mark. By improving alignment and stability, the technology aims to reduce the likelihood of costly and debilitating revision surgeries, aligning with the healthcare system’s broader goal of reducing long-term costs and improving patient quality of life.

A New Precedent for MedTech Innovation?

Perhaps the most significant long-term impact of this decision is the precedent it sets. For decades, med-tech innovators have faced a chicken-and-egg problem: securing reimbursement without widespread adoption is difficult, but achieving adoption without clear reimbursement is nearly impossible. By creating new MS-DRGs for a specific class of technology, CMS is demonstrating a more dynamic and responsive approach to valuing innovation.

This serves as a powerful signal to other companies developing AI-driven, personalized, or 3D-printed medical devices. It suggests that if a technology can demonstrate both significant clinical benefit and unique resource requirements, CMS is willing to create a bespoke payment pathway. This could spur further investment and R&D in areas that have been historically stymied by reimbursement uncertainty. As the policy change takes effect on October 1, all eyes will be on Carlsmed to see if clear reimbursement is the final catalyst needed to make personalized surgery the undisputed standard of care.